HCW Biologics Inc. (HCWB)
Total Valuation
HCW Biologics has a market cap or net worth of $64.19 million. The enterprise value is $59.30 million.
Market Cap | 64.19M |
Enterprise Value | 59.30M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
Earnings Date | May 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 35.97 million shares outstanding. The number of shares has increased by 0.26% in one year.
Shares Outstanding | 35.97M |
Shares Change (YoY) | +0.26% |
Shares Change (QoQ) | +0.05% |
Owned by Insiders (%) | 54.72% |
Owned by Institutions (%) | 2.97% |
Float | 16.94M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 111.44 |
Forward PS | 69.93 |
PB Ratio | 2.69 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 102.96 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.27.
Current Ratio | 2.56 |
Quick Ratio | 2.20 |
Debt / Equity | 0.27 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -47.00 |
Financial Efficiency
Return on equity (ROE) is -64.40% and return on invested capital (ROIC) is -68.27%.
Return on Equity (ROE) | -64.40% |
Return on Assets (ROA) | -47.70% |
Return on Capital (ROIC) | -68.27% |
Revenue Per Employee | $13,091 |
Profits Per Employee | -$448,466 |
Employee Count | 44 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.33% in the last 52 weeks. The beta is 0.92, so HCW Biologics's price volatility has been similar to the market average.
Beta (1Y) | 0.92 |
52-Week Price Change | +32.33% |
50-Day Moving Average | 1.37 |
200-Day Moving Average | 1.64 |
Relative Strength Index (RSI) | 63.53 |
Average Volume (30 Days) | 16,900 |
Short Selling Information
The latest short interest is 22,012, so 0.06% of the outstanding shares have been sold short.
Short Interest | 22,012 |
Short Previous Month | 23,960 |
Short % of Shares Out | 0.06% |
Short % of Float | 0.13% |
Short Ratio (days to cover) | 2.62 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $576,019 and -$19.73 million in losses. Loss per share was -$0.56.
Revenue | 576,019 |
Gross Profit | 576,019 |
Operating Income | -20.62M |
Pretax Income | -19.73M |
Net Income | -19.73M |
EBITDA | -18.20M |
EBIT | -19.32M |
Loss Per Share | -$0.56 |
Balance Sheet
The company has $11.22 million in cash and $6.33 million in debt, giving a net cash position of $4.89 million or $0.14 per share.
Cash & Cash Equivalents | 11.22M |
Total Debt | 6.33M |
Net Cash | 4.89M |
Net Cash Per Share | $0.14 |
Equity / Book Value | 23.87M |
Book Value Per Share | 0.66 |
Working Capital | 8.43M |
Cash Flow
In the last 12 months, operating cash flow was -$22.41 million and capital expenditures -$2.56 million, giving a free cash flow of -$24.96 million.
Operating Cash Flow | -22.41M |
Capital Expenditures | -2.56M |
Free Cash Flow | -24.96M |
FCF Per Share | -$0.70 |
Margins
Gross margin is 100.00%, with operating and profit margins of -3,579.08% and -3,425.67%.
Gross Margin | 100.00% |
Operating Margin | -3,579.08% |
Pretax Margin | -3,425.67% |
Profit Margin | -3,425.67% |
EBITDA Margin | -3,159.62% |
EBIT Margin | -3,354.29% |
FCF Margin | -4,333.94% |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.26% |
Shareholder Yield | -0.26% |
Earnings Yield | -30.74% |
FCF Yield | -38.89% |
Analyst Forecast
The average price target for HCW Biologics is $9.00, which is 411.36% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $9.00 |
Price Target Difference | 411.36% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 99.63% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
HCW Biologics has an Altman Z-Score of -0.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.56 |
Piotroski F-Score | 1 |